Publications by authors named "Michael Boxer"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

35,031

Total Likes

1,426

Extended Reach

41,746

Social Features

6
I
Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors.
Michael Boxer

EJHaem· November 2020

Videos about Article: user user

2 7 4 3

View All Article and Social Media Activity
F
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
David J Kuter, Kerry A Rogers, Michael A Boxer, Michael Choi, Richy Agajanian

Am J Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Alexey V Danilov, Habte A Yimer, Michael A Boxer, John M Burke, Sunil Babu

Clin Lymphoma Myeloma Leuk· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
Jeff P Sharman, John M Burke, Habte A Yimer, Michael A Boxer, Sunil Babu

Leuk Lymphoma· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
Leslie Padrnos, Robyn Scherber, Holly Geyer, Blake T Langlais, Amylou C Dueck, Michael Boxer

Cancer Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Ralph Boccia, Nichola Cooper, Waleed Ghanima, Michael A Boxer, Quentin A Hill

Br J Haematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiologies of Thrombocytopenia in the Community Hospital: The Experience of 1 Hematologist.
Michael Boxer, Thomas J Biuso

Am J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reflections on 45 years as a clinical hematologist.
Michael Boxer

Clin Adv Hematol Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collateral Damages by Magic Bullets: Hemolytic Uremic and Capillary Leak Syndromes After Moxetumomab Pasudotox Therapy.
Yeong-Hau H Lien, Michael Boxer

Am J Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
James B Bussel, Donald M Arnold, Michael A Boxer, Nichola Cooper, Jiri Mayer

Am J Hematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.
Robyn M Scherber, Heidi E Kosiorek, Zhenya Senyak, Amylou C Dueck, Matthew M Clark, Michael A Boxer

Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
John C Byrd, Joseph M Flynn, Thomas J Kipps, Michael Boxer, Kathryn S Kolibaba

Blood· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Jeff Sharman, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein

Blood· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Steven P Treon, Jacob D Soumerai, Zachary R Hunter, Christopher J Patterson, Leukothea Ioakimidis, Michael Boxer

Blood· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of Parkinson's disease in type 1 Gaucher disease.
Gilberto Bultron, Katherine Kacena, Daniel Pearson, Michael Boxer, Ruhua Yang

J Inherit Metab Dis· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.
Tamar H Taddei, Katherine A Kacena, Mei Yang, Ruhua Yang, Advitya Malhotra, Michael Boxer

Am J Hematol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis